Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis. 2020

Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan.

Introduction: Antimicrobial dose optimization for the treatment of sepsis remains challenging because of dynamic pharmacokinetic alterations and physiological/pathological responses of the host. Subtherapeutic plasma levels of antimicrobials are commonly observed in patients with sepsis, which potentially leads to both treatment failure and emergence of antimicrobial resistance. The knowledge of antimicrobial pharmacokinetics and pharmacodynamics is helpful in order to tailor antimicrobial dosing strategies.Areas covered: This narrative review summarizes pharmacokinetic alterations of antimicrobial agents and provides useful information on antimicrobial dose optimization. Literature was searched using PubMed database, focusing on pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in sepsis.Expert opinion: In patients with sepsis, increased volume of distribution and variable changes in renal clearance are the two major factors for antimicrobial pharmacokinetic alterations. Traditional 'one-dose-fits-all' dosing strategy is not suitable for patients with sepsis and hence individualized antimicrobial dosing adjustment is preferable. In general, the initial dose of hydrophilic antimicrobials such as ß-lactams, aminoglycosides, and vancomycin should be given at a high dose regardless of renal function. Improved methods of drug administration (e.g. extended/continuous infusion of β-lactams) help to increase the chance of pharmacodynamic target attainment. The use of therapeutic drug monitoring should be considered where available.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug
D018805 Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK. Bloodstream Infection,Pyaemia,Pyemia,Pyohemia,Blood Poisoning,Poisoning, Blood,Septicemia,Severe Sepsis,Blood Poisonings,Bloodstream Infections,Infection, Bloodstream,Poisonings, Blood,Pyaemias,Pyemias,Pyohemias,Sepsis, Severe,Septicemias

Related Publications

Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
July 1998, The Journal of infection,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
January 2003, Clinical pharmacokinetics,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
November 2003, Drug discovery today,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
October 2013, Clinical pharmacokinetics,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
January 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
July 2015, World journal of nephrology,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
May 2015, Advanced drug delivery reviews,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
March 2024, Orvosi hetilap,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
February 1990, Clinical pharmacy,
Motoki Fujii, and Toshiyuki Karumai, and Ryohei Yamamoto, and Eri Kobayashi, and Kenta Ogawa, and Mayuko Tounai, and Jeffrey Lipman, and Yoshiro Hayashi
September 2004, The Annals of pharmacotherapy,
Copied contents to your clipboard!